Mixed results for Boston Scientific:
This article was originally published in Clinica
First-quarter sales for Boston Scientific rose by 9% to $470 million, although net income dropped to $67 million, compared with $75 million in the previous period. Excluding currency effects, sales rose by 13%. Peter Nicholas, chairman and CEO, said that the results were in line with expectations. The company conceded that it was disadvantaged by the fact that it had not yet obtained marketing approval for its NIR and Radius stents in the US and Japan, but said they were making progress.